Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 188

Results For "therapy"

1903 News Found

Biocon Biologics partners Adagio to manufacture antibody for COVID-19
News | July 27, 2021

Biocon Biologics partners Adagio to manufacture antibody for COVID-19

ADG20, a novel monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses


Triastek closes US $50 Mn Series B Financing
News | July 01, 2021

Triastek closes US $50 Mn Series B Financing

In addition to supporting the ongoing development of the first IND-approved product in clinical trials, the proceeds will also be used to expand the 3D printed drug product pipeline


Dr. Reddy's announces commercial launch of 2DG
News | June 29, 2021

Dr. Reddy's announces commercial launch of 2DG

2-DG was developed by the Institute of Nuclear Medicine & Allied Sciences (INMAS), a laboratory of the Defence Research and Development Organisation (DRDO), in collaboration with Dr. Reddy's


Zydus Cadila receives tentative approval from USFDA for Pemetrexed
News | June 26, 2021

Zydus Cadila receives tentative approval from USFDA for Pemetrexed

Pemetrexed is used to treat certain types of cancers such as lung cancer, mesothelioma. It is a chemotherapy drug that works by slowing or stopping the growth of cancer cells


Glenmark receives ANDA tentative approval for Nintedanib Capsules
News | June 26, 2021

Glenmark receives ANDA tentative approval for Nintedanib Capsules

According to IQVIA sales data for the 12 month period ending April 2021, the Ofev Capsules, 100 mg and 150 mg market achieved annual sales of approximately US $1.6 billion


JB Chemicals PAT jumps by 101% to Rs101 Cr
News | June 15, 2021

JB Chemicals PAT jumps by 101% to Rs101 Cr

The company recorded revenue of Rs 528crore as compared to Rs 444 crore, registering a growth of 19% over the corresponding quarter ended 31st March 2020


Alkem launches Perampil tablets at affordable prices
News | June 11, 2021

Alkem launches Perampil tablets at affordable prices

The company has launched Perampil, at 2 mg (Rs. 49/strip of 7 tablets), 4 mg (Rs. 180/strip of 15 tablets) and 6 mg (Rs. 300/strip of 15 tablets) to improve patient access


Glenmark receives ANDA approval for theophylline extended-release tablets
News | June 07, 2021

Glenmark receives ANDA approval for theophylline extended-release tablets

Glenmark has been granted a competitive generic therapy (CGT) designation for theophylline extended-release tablets


Bayer acquires Noria and PSMA Therapeutics
News | June 07, 2021

Bayer acquires Noria and PSMA Therapeutics

Broadens company’s oncology platform of Targeted Alpha Therapies (TATs)


Jubilant to invest US $92 mn to expand sterile injectable capacity
News | June 01, 2021

Jubilant to invest US $92 mn to expand sterile injectable capacity

This investment is being made to set up a high speed 400 vials a minute injectable fill line with isolator technology